{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:44:56Z","timestamp":1792669496508,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001208","name":"Heart Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014218","name":"David C Copley Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 014195"],"award-info":[{"award-number":["P30 014195"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016463","name":"Paul M Angell Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Redox Biology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.redox.2025.103895","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T23:07:07Z","timestamp":1761433627000},"page":"103895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0987-5965","authenticated-orcid":false,"given":"Gayle S.","family":"Jameson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Danielle","family":"LeGrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise J.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy C.","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellen","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Truitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Propper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut","family":"Borazanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.redox.2025.103895_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.redox.2025.103895_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamaoncol.2019.3394","volume":"6","author":"Jameson","year":"2019","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.redox.2025.103895_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7412","article-title":"Phase II clinical trial of nab\u2010paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer","volume":"13","author":"Jameson","year":"2024","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.redox.2025.103895_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM198501173120301","article-title":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison","volume":"312","author":"Moertel","year":"1985","journal-title":"N. Engl. J. Med."},{"issue":"38","key":"10.1016\/j.redox.2025.103895_bib5","doi-asserted-by":"crossref","first-page":"13604","DOI":"10.1073\/pnas.0506390102","article-title":"Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues","volume":"102","author":"Chen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"21","key":"10.1016\/j.redox.2025.103895_bib6","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.1073\/pnas.0702854104","article-title":"Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo","volume":"104","author":"Chen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.redox.2025.103895_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17568-8","article-title":"High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: mechanisms and a phase I\/IIa study","volume":"7","author":"Polireddy","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.redox.2025.103895_bib8","article-title":"Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism","volume":"10","author":"O'Leary","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.redox.2025.103895_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3390\/antiox11050971","article-title":"Auranofin and pharmacologic ascorbate as radiomodulators in the treatment of pancreatic cancer","volume":"11","author":"Steers","year":"2022","journal-title":"Antioxidants"},{"issue":"6266","key":"10.1016\/j.redox.2025.103895_bib10","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1126\/science.aaa5004","article-title":"Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH","volume":"350","author":"Yun","year":"2015","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.redox.2025.103895_bib11","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/0008-5472.CAN-22-0408","article-title":"Selenium modulates cancer cell response to pharmacologic ascorbate","volume":"82","author":"Jankowski","year":"2022","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.redox.2025.103895_bib12","first-page":"443","article-title":"Ascorbic acid: chemistry, biology and the treatment of cancer","volume":"1826","author":"Du","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.redox.2025.103895_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccell.2017.02.018","article-title":"O2 and H2O2-Mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate","volume":"31","author":"Schoenfeld","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.redox.2025.103895_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"issue":"222","key":"10.1016\/j.redox.2025.103895_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007154","article-title":"High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.redox.2025.103895_bib16","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nbt.2377","article-title":"A cross-platform toolkit for mass spectrometry and proteomics","volume":"30","author":"Chambers","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.redox.2025.103895_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-1-4939-9236-2_19","article-title":"El-MAVEN: a fast, robust, and user-friendly mass spectrometry data processing engine for metabolomics","volume":"1978","author":"Agrawal","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.redox.2025.103895_bib18","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/cncr.24920","article-title":"Validation and application of a module of the M. D. Anderson symptom inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI)","volume":"116","author":"Wang","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.redox.2025.103895_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jphys.2015.07.001","article-title":"The Brief Pain Inventory (BPI)","volume":"62","author":"Poquet","year":"2016","journal-title":"J. Physiother."},{"key":"10.1016\/j.redox.2025.103895_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101068","article-title":"Emerging roles of lysophospholipids in health and disease","volume":"80","author":"Tan","year":"2020","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.redox.2025.103895_bib21","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2024.42.16_suppl.4165","article-title":"Does non-alcoholic fatty liver disease increase the risk for pancreatic cancer? A multi-center retrospective cohort study","volume":"42","author":"Singh","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.redox.2025.103895_bib22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-013-2070-8","article-title":"Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial","volume":"71","author":"Welsh","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.redox.2025.103895_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103375","article-title":"A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer","volume":"77","author":"Bodeker","year":"2024","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.redox.2025.103895_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029794","article-title":"Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"7","author":"Monti","year":"2012","journal-title":"PLoS One"},{"issue":"Suppl","key":"10.1016\/j.redox.2025.103895_bib25","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"8","key":"10.1016\/j.redox.2025.103895_bib26","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41366-018-0212-0","article-title":"Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor \u03b1 in high-fat-diet-fed C57BL\/6J mice","volume":"43","author":"Lee","year":"2019","journal-title":"Int. J. Obes."},{"issue":"11","key":"10.1016\/j.redox.2025.103895_bib27","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3390\/nu14112195","article-title":"Mega-dose vitamin C ameliorates nonalcoholic fatty liver disease in a mouse fast-food diet model","volume":"14","author":"Lee","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.redox.2025.103895_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.745609","article-title":"Effects of oral vitamin C supplementation on liver health and associated parameters in patients with non-alcoholic fatty liver disease: a randomized clinical trial","volume":"8","author":"He","year":"2021","journal-title":"Front. Nutr."},{"issue":"15","key":"10.1016\/j.redox.2025.103895_bib29","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.redox.2026.104395","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000}},{"DOI":"10.1016\/j.redox.2026.104395","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Redox Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231725004082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213231725004082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:39:51Z","timestamp":1773311991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213231725004082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"alternative-id":["S2213231725004082"],"URL":"https:\/\/doi.org\/10.1016\/j.redox.2025.103895","relation":{},"ISSN":["2213-2317"],"issn-type":[{"value":"2213-2317","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Redox Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.redox.2025.103895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103895"}}